| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73fbc44d96349c8b0dabbb7580d4b428 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6d56fcf675c999fdb45ec4c494a975c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b117fd09b5e7ba4644d2a8db2631c70d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fd586f34cff67a6f23bab85c9a14ddf |
| publicationDate |
2021-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3788079-A1 |
| titleOfInvention |
High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom |
| abstract |
High-affinity antibodies recognizing Programmed Death Ligand-1 (PD-1) and Lymphocyte Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 and anti-LAG-3 antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both PD-1 and LAG-3 simultaneously. Such bispecific FIT-Ig binding proteins are useful for treatment of cancer. |
| priorityDate |
2018-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |